Ribociclib
Novartis
['bcsm']
maintain; ribo+et vs et after pd on 1l cdk4/6 inhibitors in 119 mhr+#bcsm, pfs 2.7 in et vs 5.2 in et+ribo. most got fulvestrant et. the benefit seems limited to the esr1 wt group #asco22 
Breast medical oncologist @TuftsMedicalCtr | Tweets are my own | ???? ????